Nuveen LLC Takes $368,000 Position in Voyager Therapeutics, Inc. $VYGR

Key Points

• Nuveen LLC has made a new investment in Voyager Therapeutics, acquiring 108,789 shares valued at approximately $368,000, representing about 0.20% ownership in the company.
• Several institutional investors have increased their stakes in Voyager Therapeutics, with CWM LLC boosting its holdings by 856.3% to own 10,471 shares.
• Voyager Therapeutics recently reported a loss of ($0.57) EPS for the quarter, missing analysts' expectations, alongside a revenue of $5.20 million against a forecast of $9.50 million.

Nuveen LLC purchased a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 108,789 shares of the company's stock, valued at approximately $368,000. Nuveen LLC owned approximately 0.20% of Voyager Therapeutics at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in VYGR. Cubist Systematic Strategies LLC acquired a new position in Voyager Therapeutics in the fourth quarter worth $29,000. Tower Research Capital LLC TRC boosted its holdings in Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after purchasing an additional 3,077 shares during the period. CWM LLC boosted its holdings in Voyager Therapeutics by 856.3% in the first quarter. CWM LLC now owns 10,471 shares of the company's stock worth $35,000 after purchasing an additional 9,376 shares during the period. Privium Fund Management B.V. acquired a new position in Voyager Therapeutics in the first quarter worth $73,000. Finally, Tema Etfs LLC acquired a new position in Voyager Therapeutics in the fourth quarter worth $85,000. Institutional investors and hedge funds own 48.03% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wedbush decreased their price objective on shares of Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating for the company in a report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to MarketBeat, Voyager Therapeutics has a consensus rating of "Buy" and a consensus target price of $13.25.

Voyager Therapeutics Stock Performance

Shares of VYGR traded up $0.22 during midday trading on Thursday, hitting $4.38. 1,306,401 shares of the stock traded hands, compared to its average volume of 577,354. Voyager Therapeutics, Inc. has a 1-year low of $2.64 and a 1-year high of $8.27. The firm has a market capitalization of $242.96 million, a PE ratio of -2.37 and a beta of 0.90. The business's 50 day moving average price is $3.45 and its two-hundred day moving average price is $3.42.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. The firm had revenue of $5.20 million for the quarter, compared to analyst estimates of $9.50 million. As a group, equities research analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.